

Available online on 15.01.2025 at <http://jddtonline.info>

Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

Copyright © 2025 The Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited



Open Access Full Text Article



Review Article

In-vitro approaches to evaluate the anti-inflammatory potential of phytochemicals: A Review

Sriaandhal Sabalingam *

Department of Pharmacy, Faculty of Allied Health Sciences, General Sir John Kotelawala Defence University, Sri Lanka

Article Info:



Article History:

Received 23 Oct 2024
Reviewed 06 Dec 2024
Accepted 02 Jan 2025
Published 15 Jan 2025

Cite this article as:

Sabalingam S, In-vitro approaches to evaluate the anti-inflammatory potential of phytochemicals: A Review, Journal of Drug Delivery and Therapeutics. 2025; 15(1):187-192 DOI: <http://dx.doi.org/10.22270/jddt.v15i1.6956>

*Address for Correspondence:

Sriaandhal Sabalingam, Department of Pharmacy, Faculty of Allied Health Sciences, General Sir John Kotelawala Defence University, Werahara, Boralessamuwa, Sri Lanka

Abstract

Phytochemicals, bioactive compounds derived from plants, have drawn considerable attention for their ability to modulate inflammatory pathways, presenting promising alternatives for the treatment of chronic inflammatory diseases. Inflammation, a complex biological response to injury or infection, involves a cascade of cellular and molecular events mediated by enzymes, cytokines, and reactive species. *In vitro* assays provide an essential platform for screening and investigating the anti-inflammatory potential of phytochemicals, offering valuable insights into their mechanisms of action. Commonly used techniques include the inhibition of protein denaturation and membrane stabilization, which evaluate the ability of compounds to prevent structural damage to proteins and cell membranes. Enzymatic assays, such as cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) inhibition tests, focus on the suppression of key enzymes involved in arachidonic acid metabolism, thereby reducing the production of pro-inflammatory mediators like prostaglandins and leukotrienes. Other assays, like proteinase and hyaluronidase inhibition tests, assess the ability of compounds to block enzymes contributing to tissue degradation and inflammation. These assays offer robust, reproducible frameworks for evaluating phytochemicals in preclinical research, helping to identify compounds with potential therapeutic value. However, their limitations, such as lack of *in vivo* context and inter-assay variability, necessitate their integration with complementary studies to validate findings and understand their translational significance.

Keywords: Phytochemicals, *in vitro* methods, anti-inflammatory activity, protein denaturation, membrane stabilization

Introduction

Inflammation is a natural defence mechanism for tissue damage brought on by harmful chemicals, microorganisms, or physical trauma. To eliminate the irritants and prepare the body for tissue healing, the body reacts by inactivating or destroying the invasive organisms. It is brought on by migrant cells and wounded tissue releasing chemical mediators. The symptoms of inflammation include heat, redness, discomfort, swelling, and disruption of physiological processes ¹. The inflammatory process involves a series of events in which the metabolism of arachidonic acid plays a critical role. The Cyclooxygenase (COX) pathway converts arachidonic acid into prostaglandins and thromboxane A₂, whereas the 5-lipoxygenase (5-LOX) pathway converts it into leukotrienes (LTs) and eicosanoids. In a variety of inflammatory reactions, these metabolites play an important role as chemical mediators. Current anti-inflammatory medications successfully block both enzyme routes and reduce symptoms, but they often cause significant adverse effects ². There is a need to discover medicines that have fewer adverse effects as a result.

Plants are the source of bioactive substances known as phytochemicals. Multiple studies have been conducted on the anti-inflammatory properties of several plants. The anti-inflammatory qualities of phytochemicals have drawn attention because of their bioactive components, which include terpenoids, alkaloids, and flavonoids ³. Phytochemicals are interesting options for the treatment of illnesses related to inflammation because of their capacity to modulate inflammation by blocking pro-inflammatory mediators and signalling pathways ⁴.

In vitro studies are a key investigation tool, particularly during the early phases of drug development and scientific investigations, because they have several advantages over *in vivo* tests. *In vitro* experiments are conducted in a controlled environment, such as cell cultures or biochemical assays, allowing researchers to isolate specific variables without interference from the complex interactions present in living organisms ⁵. Studies conducted *in vitro* are less expensive than those conducted *in vivo*. They are a cost-effective option for early research since they do not require the costs of housing and caring for animal models or carrying out human trials. This review focuses on five widely used *in vitro* assays: inhibition of protein denaturation,

membrane stabilization, Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) inhibition, proteinase inhibition, and hyaluronidase inhibition⁶⁻¹⁰. These assays are critical for elucidating the molecular mechanisms of phytochemicals and their potential therapeutic applications. This review aims to explore various *in vitro* methods used to evaluate the anti-inflammatory activity of phytochemicals, discussing their mechanisms of action and the challenges involved.

In-vitro methods to measure anti-inflammatory effects of phytochemicals

Inhibition of Protein Denaturation Assay

The Inhibition of Protein Denaturation Assay is a widely used *in-vitro* method to evaluate the anti-inflammatory potential of compounds, particularly phytochemicals. Whenever proteins undergo denaturation, they lose their tertiary structure because of external stress like heat, pH changes, or chemicals. This leads to the loss of their functional properties. Protein denaturation is a common result of inflammation and oxidative stress, which exacerbates tissue damage and progresses diseases¹¹. This experiment involves applying heat or chemical stress to a protein solution, usually egg albumin or bovine serum albumin (BSA), to determine the ability of the compound to inhibit protein denaturation. The test compound is introduced to the protein solution, and the extent of denaturation is assessed by measuring changes in absorbance, turbidity, or the loss of enzymatic activity¹². The compound's protective effect is determined by comparing the absorbance or activity levels in the presence of the test compound to a control.

A lower absorbance or higher enzyme activity in the presence of the compound indicates its potential to inhibit protein denaturation. In this test, phytochemicals like flavonoids, polyphenols, and alkaloids showed promising results, exhibiting their protective and anti-inflammatory qualities by stabilizing proteins and preventing their denaturation¹³. The protein model that is frequently utilized is bovine serum albumin (BSA). The protein solution is heated at 70°C for 10 minutes to cause denaturation.

A reaction mixture contains 1000 µL (100–500 µg/ml) of plant extract, 200 µL of egg albumin or 450 µL (5% w/v aqueous solution) of bovine serum albumin, and 1400 µL of phosphate buffered saline in different concentrations. As a negative control, distilled water is used in place of the extracts in the mixture above. Afterward, the mixtures are incubated at 37 °C for 15 min and then heated at 70°C for 5 min. Once the protein solution has cooled to room temperature, a spectrophotometer is used to measure the degree of denaturation at 660 nm¹⁴. Standard anti-inflammatory drugs, such as ibuprofen or diclofenac sodium, are utilized for comparison. Percentage inhibition of protein denaturation is calculated using following formula.

$$\text{Inhibition (\%)} = \frac{(\text{Absorbance of control} - \text{Absorbance of sample})}{\text{Absorbance of control}} \times 100$$

Despite being an easy and economical technique, this assay fails to give any direct insights into cellular pathways or *in vivo* relevance. It does, however, function

as an initial screening method for substances with anti-inflammatory qualities.

Membrane Stabilization Method

The membrane stabilization method is a widely used technique for evaluating the anti-inflammatory properties of herbal extracts, synthetic compounds, and pharmaceutical preparations. The theory behind this technique is that certain substances can prevent biological membranes from lysing when they are subjected to osmotic, chemical, or physical stress. Red blood cell membranes are a suitable model for this assay because of their structural similarities to lysosomal membranes¹⁵⁻¹⁶.

Immune cell activation and the production of inflammatory mediators are two characteristics of inflammation, a complex biological reaction to tissue damage or infection. Intracellular organelles called lysosomes are essential to this process because they release hydrolytic enzymes that cause tissue destruction. Inflammatory reactions can be reduced by stabilizing lysosomal membranes during inflammation, which stops these enzymes from leaking out. Therefore, a compound's capacity to stabilize erythrocyte membranes is an alternative for its anti-inflammatory properties¹⁷.

In the membrane stabilization assay, human erythrocytes are usually exposed to heat or hypotonic solutions, which cause haemolysis by rupturing the erythrocyte membrane. The membrane stabilization method has the following benefits: it is easy to use, economical, and repeatable. Furthermore, it is an ethical substitute for the initial screening of anti-inflammatory medications because it does not require the use of complex animal models. But it has limitations, like not being able to take into consideration the full inflammatory cascade or the test compound's systemic effects¹⁸.

I. Hypotonic solution induced haemolysis

This technique exposes human erythrocytes to hypotonic solutions, which cause water to enter the cells and cause an osmotic imbalance. This leads to swelling, disruption of the membrane, and subsequent release of haemoglobin, a process termed haemolysis. Anti-inflammatory compounds can prevent or reduce haemolysis by stabilizing the erythrocyte membrane and maintaining its structural integrity.

After that, an erythrocyte suspension is made and incubated with the test chemical while a hypotonic solution is present. To separate intact cells from the supernatant, the reaction mixture is centrifuged at 3000 rpm following incubation at a particular temperature and time (usually 37°C for 30 minutes). A spectrophotometer is used to measure the absorbance of the released haemoglobin in the supernatant at 540 nm in order to quantify the degree of haemolysis. The haemolysis percentage is computed in relation to a control sample that does not contain the test drug¹⁹. The following formula is used to calculate the percentage inhibition of haemolysis, which is a sign of membrane stabilization:

$$\% \text{ protection} = \frac{100 - \text{Optical density of drug treated sample}}{\text{Optical density of control}} \times 100$$

II. Heat induced haemolysis

Inflammatory responses often involve cellular damage and membrane destabilization caused by physical or biochemical stress. During inflammation, lysosomal enzymes are released due to membrane lysis, which exacerbates tissue damage. Compounds that stabilize membranes can potentially reduce this damage by preventing lysosomal enzyme release. In the heat-induced haemolysis assay, the ability of a compound to protect erythrocyte membranes from heat-induced lysis serves as an indirect indicator of its anti-inflammatory potential²⁰.

A 10% erythrocyte suspension is prepared and incubated with the test compound in an isotonic buffer. Control samples (without the test compound) are included for comparison. The test samples are subjected to heat stress by incubating them at elevated temperatures, typically 54°C, for a fixed duration (usually 30 minutes). Following incubation, the samples are cooled to room temperature and centrifuged to separate intact cells from the supernatant. The extent of haemolysis is determined by measuring the absorbance of released haemoglobin in the supernatant at 540 nm using a spectrophotometer.

The percentage inhibition of haemolysis, which reflects the membrane-stabilizing activity of the test compound, is calculated using the formula²¹:

$$\% \text{ Inhibition of haemolysis} = \frac{(\text{Absorbance control} - \text{Absorbance test})}{\text{Absorbance control}} \times 100$$

$$\% \text{ Inhibition of haemolysis} = 100 \times [1 - (\text{OD}_1 - \text{OD}_2) / (\text{OD}_3 - \text{OD}_1)]$$

Where OD₁ = Optical density of unheated test sample

OD₂ = Optical density of heated test sample

OD₃ = Optical density of heated control sample

Assay of Proteinase Inhibition

Proteinases and other proteolytic enzymes contribute to tissue damage, facilitate immune cell migration to inflammatory areas, and break down extracellular matrix components, all of which are important aspects of inflammatory processes. Compounds that inhibit proteinase activity can mitigate these effects, making proteinase inhibition assays valuable tools in pharmacological and biochemical research. The assay is based on the ability of a test compound to inhibit the activity of proteinases, such as trypsin or chymotrypsin, on a specific protein substrate. Proteinase activity is commonly measured by detecting the cleavage products of the substrate, either spectrophotometrically, fluorometrically, or by other analytical methods. The reduction in enzymatic activity in the presence of the test compound indicates its inhibitory potential²².

In this experiment, commercially available proteolytic enzymes such as papain, chymotrypsin, or trypsin are frequently used. To maintain its optimum enzymatic activity, the enzyme is dissolved in an appropriate buffer, such as Tris-HCl buffer or phosphate-buffered saline (PBS). Casein, bovine serum albumin (BSA), and synthetic chromogenic substrates such as N α -Benzoyl-DL-arginine-p-nitroanilide (BAPNA) are examples of

common substrates. A buffer is used to dissolve the substrate at a concentration high enough to allow for enzymatic cleavage. To enable binding and possible inhibition, the test substance is incubated with the enzyme for a predetermined amount of time at 37°C. The substrate is added to start the reaction after pre-incubation. In parallel, a control response is conducted without the test chemical²³⁻²⁴.

To ensure sufficient enzymatic cleavage of the substrate, the reaction mixture is incubated at 37°C for a predetermined amount of time, such as 30 minutes. By adding a stop solution, like trichloroacetic acid (TCA), which precipitates undigested proteins or inhibits enzyme activity, the reaction is stopped. A particular wavelength, such as 410 nm, is used to monitor the release of chromogenic compounds. Following the precipitation of undigested proteins, the turbidity decreases for casein or BSA as substrates is evaluated spectrophotometrically at 280 nm. The percentage inhibition of proteinase inhibitory activity is calculated using the following equation²⁵⁻²⁶.

$$\text{Inhibition (\%)} = \frac{(\text{Absorbance of control} - \text{Absorbance of sample})}{\text{Absorbance of control}} \times 100$$

Assay of Hyaluronidase Inhibition

The enzyme hyaluronidase catalyzes the breakdown of hyaluronic acid, an essential part of the extracellular matrix that keeps tissues hydrated, elastic, and intact²⁷. Excessive activity of hyaluronidase is linked to a wide range of clinical conditions such as arthritis and skin aging, as well as inflammation and tissue damage²⁸. Hyaluronidase inhibition can lessen these effects, which makes this assay a valuable tool for study in pharmacology and cosmetics. The assay measures a compound's capacity to prevent hyaluronic acid from being broken down by hyaluronidase. The breakdown of hyaluronic acid yields smaller oligosaccharides that can be identified by precipitation processes, colorimetry, or spectrophotometry. The test compound's inhibitory impact on hyaluronidase is indicated by a decrease in degradation in its presence²⁹.

Hyaluronic acid serves as the substrate in this test, and the assay is started once the substrate has been added. Samples of plant extract (5 mg) are dissolved in 250 μ L of dimethylsulfoxide. The samples are produced by dissolving them in sodium phosphate buffer (200 mM, pH 7) at different concentrations (100, 200, 300, 400, and 500 μ g/mL). Sample solution (25 μ L) is combined with hyaluronidase (4U/mL, 100 μ L) and incubated for 10 minutes at 37°C³⁰⁻³¹. To activate the enzyme, some researchers have added calcium chloride at 2.5 mM, 1.2 μ L³², or 12.5 mM, 50 μ L³³. The mixture is then incubated for another 20 minutes at 37 °C. The inclusion of CaCl₂ has been left out by some researchers.

Subsequently, the substrate, a hyaluronic acid solution (0.03% in 300 mM sodium phosphate, pH 5.4, 100 μ L), is added to start the reaction, and it is then incubated for 45 minutes at 37°C. Acid albumin solution (0.1%) in sodium acetate (24 mM), pH 3.8, 1 mL) is then used to precipitate the undigested hyaluronic acid. Absorbance is measured at 600 nm following a 10-minute incubation period at room temperature. For maximum inhibition, the

absorbance measurement without the enzyme is utilized as a control value. The assay's performance is confirmed by using either quercetin or indomethacin as the positive control³¹.

The percentage inhibition of hyaluronidase activity is calculated as:

$$\text{Inhibition (\%)} = \frac{\text{Absorbance of sample}}{\text{Absorbance of control}} \times 100$$

Assay of Cyclooxygenase (COX) and 5-Lipoxygenase (5-LOX) Inhibition

Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) enzyme inhibition is a commonly used technique to assess a compound's anti-inflammatory potential. These two enzymes are essential for the metabolism of arachidonic acid because they generate the important inflammatory mediators prostaglandins and leukotrienes, respectively³⁴. These assays are crucial in pharmacological and drug development research because drugs can have strong anti-inflammatory effects by blocking these enzymes. The tests for COX and 5-LOX inhibition are essential for finding new anti-inflammatory medications, especially dual inhibitors that target both enzymes. The potential for dual inhibitors to lessen gastrointestinal adverse effects linked to selective COX inhibition while offering more extensive anti-inflammatory effects makes them desirable³⁵⁻³⁶.

I. COX Inhibition Assay:

There are two primary isoforms of cyclooxygenase: constitutively produced COX-1, which maintains physiological processes such as protecting the stomach mucosa, and inducible COX-2, which is primarily engaged in inflammation and pain. The COX inhibition assay quantifies a compound's capacity to prevent these enzymes from converting arachidonic acid to prostaglandins³⁷. Enzyme extracts from biological tissues or commercially available pure COX enzymes (COX-1 and COX-2) are used. In the assay, the enzyme is incubated with arachidonic acid (substrate) either with or without the test substance present. To speed up the process, hematin or other cofactors are introduced³⁸⁻³⁹. Prostaglandin synthesis is measured by enzyme immunoassay, colorimetric, or fluorometric techniques. The reaction product is usually combined with a chromogenic substrate, like N,N-dimethyl-p-phenylenediamine (DMPD), to create a detectable color shift for colorimetric detection. In comparison to a control response in which the test substance is absent, the percentage inhibition of prostaglandin synthesis is computed⁴⁰.

II. 5-LOX Inhibition Assay:

5-LOX is an enzyme that converts arachidonic acid into pro-inflammatory mediators called leukotrienes, which have been associated in allergic responses, asthma, and arthritis. The 5-LOX inhibition test assesses a compound's capacity to prevent the formation of leukotrienes⁴¹. Purified 5-LOX or leukocyte enzyme extracts (such as human polymorphonuclear leukocytes or rat basophilic leukemia cells) are frequently utilized. In the presence of the test substance, the enzyme is incubated with either linoleic acid or arachidonic acid

(substrate). Leukotriene biosynthesis intermediates, hydroperoxyeicosatetraenoic acids (HPETEs), are produced and quantified using high-performance liquid chromatography (HPLC) or spectrophotometry at 234 nm (UV absorbance). Leukotriene levels can also be found using particular enzyme-linked immunosorbent tests (ELISAs). In comparison to the control, the percentage suppression of leukotriene or HPETE generation is computed⁴²⁻⁴⁴.

Conclusion

In vitro assays are indispensable for evaluating the anti-inflammatory potential of phytochemicals, offering valuable insights into their mechanisms of action. The methods discussed in this review, including inhibition of protein denaturation, membrane stabilization, COX and 5-LOX inhibition, proteinase inhibition, and hyaluronidase inhibition, provide a comprehensive framework for preclinical studies. While *in vitro* models offer valuable insights, several challenges need to be addressed: Many *in vitro* models use immortalized cell lines or animal-derived cells, which may not fully replicate the complexity of human inflammation. The lack of a complete immune system and tissue-specific responses is a limitation. Phytochemicals often have low bioavailability, and their effects can vary depending on their absorption, distribution, metabolism, and excretion. *In vitro* studies may not always account for these factors. The concentration of phytochemicals used in *in vitro* studies is often much higher than what is achievable in humans. This raises concerns about the translation of *in vitro* findings to clinical settings.

Future research in this area should focus on development of more physiologically relevant models: Integrating co-culture systems, organ-on-a-chip technology, and 3D cell cultures can provide more accurate models for studying phytochemical effects on inflammation. Although *in vitro* results are promising, clinical studies are needed to confirm the therapeutic potential of phytochemicals. Clinical trials that assess the bioavailability, efficacy, and safety of phytochemicals in humans are essential for translating *in vitro* findings into real-world applications.

Grant support or other sources of funding: None

Declarations of any conflicts of interest: None

Informed Consent Statement: Not applicable.

Data Availability Statement: The data supporting in this paper are available in the cited references.

Ethics approval: Not applicable.

References

- Chandra S, Chatterjee P, Dey P, Bhattacharya S. Evaluation of *in vitro* anti-inflammatory activity of coffee against the denaturation of protein. *Asian Pac J Trop Biomed* 2012;2. [https://doi.org/10.1016/S2221-1691\(12\)60154-3](https://doi.org/10.1016/S2221-1691(12)60154-3)
- Sankar Akula U, Odhav B. *In vitro* 5-Lipoxygenase inhibition of polyphenolic antioxidants from undomesticated plants of South Africa. Aqueous and methanolic extracts of 18 leafy vegetables from South Africa were investigated for their free radical scavenging activity, total phenolic content and anti-inflammatory properties. vol. 2. 2008.

3. Singh S, Bansal A, Singh V, Chopra T, Poddar J. Flavonoids, alkaloids and terpenoids: a new hope for the treatment of diabetes mellitus. *J Diabetes Metab Disord* 2022;21:941-50. <https://doi.org/10.1007/s40200-021-00943-8> PMID:35673446 PMCID:PMC9167359
4. Rodríguez-Negrete EV, Morales-González Á, Madrigal-Santillán EO, Sánchez-Reyes K, Álvarez-González I, Madrigal-Bujaidar E, et al. Phytochemicals and Their Usefulness in the Maintenance of Health. *Plants* 2024;13. <https://doi.org/10.3390/plants13040523> PMID:38498532 PMCID:PMC10892216
5. Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, et al. Erratum: Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma, *Cell*, 2018; 175(4):998-1013.e20, (S0092867418313941) (10.1016/j.cell.2018.10.038). *Cell* 2019;176:404. <https://doi.org/10.1016/j.cell.2018.12.034> PMID:30633907 PMCID:PMC6647017
6. Kalf RRR, Vreman RA, Delnoij DMJ, Bouvy ML, Goettsch WG. Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision-making of oncology medicines. *Pharmacol Res Perspect* 2021;9. <https://doi.org/10.1002/prp2.742> PMID:33749172 PMCID:PMC7982865
7. Sarveswaran R, Banukie Jayasuriya W, J A B N JW. In vitro assays to investigate the anti-inflammatory activity of herbal extracts: A Review. *Jayasuriya et al World Journal of Pharmaceutical Research* 2017;6:131. <https://doi.org/10.20959/wjpr201717-10058>.
8. Pillai LS, Nair BR. In-vitro anti-inflammatory studies in *Cleome viscosa* L. and *Cleome burmanni* W. & A. (Cleomaceae). *International Journal of Pharmaceutical Sciences and Research*. 2014 Jan 1;5(11):4998-5003.
9. Jogdand SS, Pagar J, Shinde GP, Jaggi SM, Mhaismale S. IN-VITRO ASSAYS TO INVESTIGATE ANTI-INFLAMMATORY ACTIVITY OF HERBAL EXTRACTS. vol. 10. 2022.
10. Saraswati, Giriwono PE, Iskandriati D, Tan CP, Andarwulan N. Sargassum seaweed as a source of anti-inflammatory substances and the potential insight of the tropical species: A review. *Mar Drugs* 2019;17. <https://doi.org/10.3390/md17100590> PMID:31627414 PMCID:PMC6835611
11. Hasan MM, Islam ME, Hossain MS, Akter M, Rahman MAA, Kazi M, et al. Unveiling the therapeutic potential: Evaluation of anti-inflammatory and antineoplastic activity of *Magnolia champaca* Linn's stem bark isolate through molecular docking insights. *Heliyon* 2024;10. <https://doi.org/10.1016/j.heliyon.2023.e22972> PMID:38169693 PMCID:PMC10758728
12. Kalaskar M, Redasani V, Ayyanar M, Ghante M, Firke S, Agrawal K, et al. Isolation and Characterization of Anti-Inflammatory Compounds from *Ficus microcarpa* L.f. Stem Bark. *Plants* 2023;12. <https://doi.org/10.3390/plants12183248> PMID:37765413 PMCID:PMC10538222
13. Akbar A, Gul Z, Chein SH, Sadiq MB. Investigation of Anti-Inflammatory Properties, Phytochemical Constituents, Antioxidant, and Antimicrobial Potentials of the Whole Plant Ethanolic Extract of *Achillea santolinoides* subsp. *wilhelmsii* (K. Koch) Greuter of Balochistan. *Oxid Med Cell Longev* 2023;2023. <https://doi.org/10.1155/2023/2567333>
14. Banerjee S, Biswas S, Chanda A, Das A, Adhikari A. Evaluation of phytochemical screening and anti inflammatory activity of leaves and stem of *Mikania scandens* (L.) wild. *Ann Med Health Sci Res* 2014;4:532. <https://doi.org/10.4103/2141-9248.139302> PMID:25221699 PMCID:PMC4160675
15. Anosike CA, Obidoa O, Ezeanyika LU. Membrane stabilization as a mechanism of the anti-inflammatory activity of methanol extract of garden egg (*Solanum aethiopicum*). *DARU, Journal of Pharmaceutical Sciences* 2012;20. <https://doi.org/10.1186/2008-2231-20-76> PMID:23351977 PMCID:PMC3556049
16. Aidoo DB, Konja D, Henneh IT, Ekor M. Protective Effect of Bergapten against Human Erythrocyte Hemolysis and Protein Denaturation in Vitro. *Int J Inflam* 2021;2021. <https://doi.org/10.1155/2021/1279359> PMID:34970434 PMCID:PMC8714387
17. Fujiati F, Haryati H, Joharman J, Utami SW. In Vitro Metabolite Profiling and Anti-Inflammatory Activities of *Rhodomyrtus Tomentosa* with Red Blood Cell Membrane Stabilization Methods. vol. 11. 2022. <https://doi.org/10.52547/rbmb.11.3.502> PMID:36718296 PMCID:PMC9883021
18. Hossain MM, Ahamed SK, Dewan SMR, Hassan MM, Istiaq A, Islam MS, et al. In vivo antipyretic, antiemetic, in vitro membrane stabilization, antimicrobial, and cytotoxic activities of different extracts from *Spilanthes paniculata* leaves. *Biol Res* 2014;47. <https://doi.org/10.1186/0717-6287-47-45> PMID:25299748 PMCID:PMC4177068
19. Moualek I, Iratni Aiche G, Mestar Guechaoui N, Lahcene S, Houali K. Antioxidant and anti-inflammatory activities of *Arbutus unedo* aqueous extract. *Asian Pac J Trop Biomed* 2016;6:937-44. <https://doi.org/10.1016/j.apjtb.2016.09.002>
20. Yesmin S, Paul A, Naz T, Rahman ABMA, Akhter SF, Wahed MII, et al. Membrane stabilization as a mechanism of the anti-inflammatory activity of ethanolic root extract of *Choi* (*Piper chaba*). *Clinical Phytoscience* 2020;6. <https://doi.org/10.1186/s40816-020-00207-7>
21. Sharma V, Singh M. In vitro antiarthritic and hemolysis preventive: Membrane stabilising efficacy of ethanolic root extract of *operculina turpethum*. 2014.
22. Berdyshev IM, Karaseva MA, Demidyuk I V. Assay for Protealysin-like Protease Inhibitor Activity. *Bio Protoc* 2022;12. <https://doi.org/10.21769/BioProtoc.4528> PMID:36313197 PMCID:PMC9548520
23. Assiry AA, Bhavikatti SK, Althobaiti FA, Mohamed RN, Karobari MI. Evaluation of in Vitro Antiprotease Activity of Selected Traditional Medicinal Herbs in Dentistry and Its in Silico PASS Prediction. *Biomed Res Int* 2022;2022. <https://doi.org/10.1155/2022/5870443> PMID:35707383 PMCID:PMC9192215
24. Zhang G. Protease Assays. 2012 May 1 [Updated 2012 Oct 1]. In: Markossian S, Grossman A, Arkin M, et al, editors. *Assay Guidance Manual* [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-. Bookshelf URL: <https://www.ncbi.nlm.nih.gov/books/>
25. Yamamoto KZ, Yasuo N, Sekijima M. Screening for Inhibitors of Main Protease in SARS-CoV-2: In Silico and In Vitro Approach Avoiding Peptidyl Secondary Amides. *J Chem Inf Model* 2022;62:350-8. <https://doi.org/10.1021/acs.jcim.1c01087> PMID:35015543
26. Eubanks M, Cook C. Assay for proteinase inhibition in *Tripsacum-Zea diploperennis* × maize hybrids resistant to Western corn rootworm. *Maize Genetics Cooperation Newsletter* [Internet]. 2000 Jan 1;(74):30-1. 27. Jirachayamaethasakul C, Ding Y, Hwang O, Im ST, Jang Y, Myung SW, et al. In vitro screening of elastase, collagenase, hyaluronidase, and tyrosinase inhibitory and antioxidant activities of 22 halophyte plant extracts for novel cosmeceuticals. *Fish Aquatic Sci* 2020;23. <https://doi.org/10.1186/s41240-020-00149-8>
28. Vinardell MP, Maddaleno AS, Mitjans M. Harmonizing In Vitro Techniques for Anti-Aging Cosmetic Ingredient Assessment: A Comprehensive Review. *Cosmetics* 2024;11. <https://doi.org/10.3390/cosmetics11050170>
29. Akkol EK, Günbatan T, Gürbüz İ, Duman H, Kılıç CS, İlhan M. In Vitro Enzyme Inhibitory Activity of *Ten Ferulago* W. Koch Species Growing in Turkey. *Brazilian Archives of Biology and Technology* 2022;65. <https://doi.org/10.1590/1678-4324-202210207>
30. Fariza IN, J. Fadzureena, A. Zunoliza, A. Luqman Chuah, K.Y. Pin, I. Adawiah. Anti-inflammatory Activity of the Major Compound from Methanol Extract of *Phaleria macrocarpa* Leaves. *Journal of Applied Sciences* [Internet]. 2012 May 15;12(11):1195-8. <https://doi.org/10.3923/jas.2012.1195.1198>
31. Salvamani S, Gunasekaran B, Shukor MY, Shaharuddin NA, Sabullah MK, Ahmad SA. Anti-HMG-CoA reductase, antioxidant, and anti-inflammatory activities of *amaranthus viridis* leaf extract

- as a potential treatment for hypercholesterolemia. Evidence-Based Complementary and Alternative Medicine 2016;2016. <https://doi.org/10.1155/2016/8090841> PMID:27051453 PMCID:PMC4804040
32. Campos JF, Das Santos UP, Da Rocha PDS, Damião MJ, Balestieri JBP, Cardoso CAL, et al. Antimicrobial, Antioxidant, Anti-Inflammatory, and Cytotoxic Activities of Propolis from the Stingless Bee *Tetragonisca fiebrigi* (Jataí). Evidence-Based Complementary and Alternative Medicine 2015;2015. <https://doi.org/10.1155/2015/296186> PMID:26185516 PMCID:PMC4491730
33. Wiem A, Smail A, Mnif W, Faleiro ML, Wissem M. Antioxidant, anti-inflammatory and anti-acetylcholinesterase activities of leaf, flower and seed aqueous extracts of *Lawsonia inermis* from Tunisia. 2014.
34. Nguyen HT, Vu TY, Chandi V, Polimati H, Tatipamula VB. Dual COX and 5-LOX inhibition by clerodane diterpenes from seeds of *Polyalthia longifolia* (Sonn.) Thwaites. *Sci Rep* 2020;10. <https://doi.org/10.1038/s41598-020-72840-8> PMID:32994508 PMCID:PMC7524750
35. Fiorucci S, Meli R, Bucci M, Cirino G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? 2001.
36. Bošković J, Dobričić V, Mihajlović M, Kotur-Stevuljević J, Čudina O. Synthesis, Evaluation of Enzyme Inhibition and Redox Properties of Potential Dual COX-2 and 5-LOX Inhibitors. *Pharmaceuticals* 2023;16. <https://doi.org/10.3390/ph16040549> PMID:37111306 PMCID:PMC10142505
37. Mogana R, Teng-Jin K, Wiart C. The Medicinal Timber *Canarium patentinervium* Miq. (Burseraceae Kunth.) Is an Anti-Inflammatory Bioresource of Dual Inhibitors of Cyclooxygenase (COX) and 5-Lipoxygenase (5-LOX) . *ISRN Biotechnol* 2013;2013:1-8. <https://doi.org/10.5402/2013/986361> PMID:25937987 PMCID:PMC4393036
38. Sekhar S, R NS, S PH. In vitro antioxidant activity, lipoxygenase, cyclooxygenase-2 inhibition and DNA protection properties of *Memecylon* species. 2013.
39. Awang Hamsin DEZ, Abdul Hamid R, Saiful Yazan L, Mat Taib CN, Yeong LT. *Ardisia crispa* roots inhibit cyclooxygenase and suppress angiogenesis. *BMC Complement Altern Med* 2014;14. <https://doi.org/10.1186/1472-6882-14-102> PMID:24641961 PMCID:PMC4000009
40. Cuendet M, Mesecar AD, DeWitt DL, Pezzuto JM. An ELISA method to measure inhibition of the COX enzymes. *Nat Protoc* 2006;1:1915-21. <https://doi.org/10.1038/nprot.2006.308> PMID:17487176
41. Fang WF, Douglas IS, Wang CC, Kao HC, Chang YT, Tseng CC, et al. 5-lipoxygenase activating protein (FLAP) dependent leukotriene biosynthesis inhibition (MK591) attenuates lipid a endotoxin-induced inflammation. *PLoS One* 2014;9. <https://doi.org/10.1371/journal.pone.0102622> PMID:25025775 PMCID:PMC4099325
42. Jiang Z, Yin X, Jiang Q. Natural Forms of Vitamin E and 13'-Carboxychromanol, a Long-Chain Vitamin E Metabolite, Inhibit Leukotriene Generation from Stimulated Neutrophils by Blocking Calcium Influx and Suppressing 5-Lipoxygenase Activity, Respectively. *The Journal of Immunology* 2011;186:1173-9. <https://doi.org/10.4049/jimmunol.1002342> PMID:21169551 PMCID:PMC4050064
43. Garscha U, Romp E, Pace S, Rossi A, Temml V, Schuster D, et al. Pharmacological profile and efficiency in vivo of diflapolin, the first dual inhibitor of 5-lipoxygenase-activating protein and soluble epoxide hydrolase. *Sci Rep* 2017;7. <https://doi.org/10.1038/s41598-017-09795-w> PMID:28839250 PMCID:PMC5571211
44. Werz O. Inhibition of 5-Lipoxygenase Product Synthesis by Natural Compounds of Plant Origin n.d. <https://doi.org/10.1055/s-2007-990242> PMID:17939102